Retatrutide

top pick

Also seen as: LY3437943, reta, triple G, GGG tri-agonist · Not approved; phase 3 ongoing

The Dose Guy’s verdict
Aug 28, 2026
8 sources

Yes, enthusiastically, if the job in front of you is a heavy cut. Retatrutide is the strongest weight-loss drug anyone has put numbers on, and at this point it is safe and well understood: the community has years of collective mileage on it and the trial numbers to match. The one thing tirzepatide still holds over it is certainty, an approval, longer outcome data, and a gentler side profile. So the split is simple: already lean, or want the surest road, run tirzepatide; carrying real weight you want gone fast, run retatrutide.

Would I take it?Yes, and it's not close.

What it is

One peptide, three receptors. Retatrutide is Eli Lilly’s triple agonist: it hits GLP-1, GIP, and glucagon at once. The GLP-1 and GIP arms are the familiar machinery, the same territory semaglutide and tirzepatide work: the stomach slows, the food noise switches off, portions shrink without you negotiating with yourself. The glucagon arm is the new move, and it spends energy instead of just cutting intake, nudging your metabolic rate up so the deficit comes from both directions.

That third receptor is why retatrutide out-cuts everything before it, and also why it runs a little hotter than tirzepatide: more heart-rate signal, more sweating, a bit more gut complaint for the extra effect. The lineage is easy to hold. Semaglutide hit one receptor, tirzepatide added a second, retatrutide adds the third, and each addition has raised the ceiling.

What the research shows

The headline numbers are the largest any weight-loss drug has ever printed, and the base under them keeps growing, with phase 3 results now landing:

24.2% mean weight loss at 48 weeks on 12 mg, versus 2.1% on placebo. On that dose every single participant lost at least 5% of body weight, and 83% lost at least 15%.NEJM 2023 · phase 2 · n=338
In the liver-fat substudy, 24 weeks on 12 mg cut liver fat by 82.4% against a 0.3% rise on placebo, and 86% of that arm got back under the 5% line that counts as a normal liver.Nat Med 2024 · phase 2a · n=98
The first phase 3 to publish, in type 2 diabetes: 15.3% of body weight gone in 40 weeks on 12 mg versus 2.6% on placebo, and 91% of participants finished the treatment period still on the drug.Lancet 2026 · phase 3 · n=537
No head-to-head trial against tirzepatide or semaglutide exists; every published comparison is an indirect meta-analysis. The split I opened with is my read of the two programs side by side, not one trial’s answer.as of Aug 2026

Realistic protocols

Dose to your hunger, not to a schedule. Retatrutide’s whole job is making eating less feel effortless, so the right dose is the lowest one that does that, found from below. Start at 1 or 2 mg a week, subcutaneous. If hunger stays quiet there, stay there: holding a low dose that works is winning, not underdosing, and the weight comes off just the same over the months. When real hunger creeps back, step up a milligram or two and give the new dose about a month before judging it, because blood levels keep building for weeks after a raise. Plenty of people never see the top half of the range; 12 mg exists because a trial needed a ceiling, not because you do.

Two pieces of living-on-it advice. First, alcohol: skip it. Drinking on retatrutide sits badly on an already slowed gut, and most people find booze simply stops feeling good on it, a fast lane to nausea and a wrecked evening. Second, protect your muscle: a cut this fast will take lean mass with it if you let it, so keep protein high and keep lifting the whole way down.

If the appetite grip fades after months on it, the community answer is adding cagrilintide, an amylin analog that restores the hunger control, rather than chasing the fade up retatrutide’s dose range.

Start1–2 mg/wkOnce weekly, sub-q. The low start is what keeps your gut on side.
Holdyour doseIf hunger stays quiet, stay. A low dose that works is winning.
Raise+1–2 mgOnly when real hunger returns. Give each change a month before judging it.
Ceiling12 mg/wkTrial max. GI misery zone, rarely worth it.

Side effects

Mostly the familiar GLP-1 profile, plus a little heat from the glucagon arm:

commonNausea, sluggish digestion, and the occasional rough day of vomiting or constipation, dose-related and clustered around raises. Slower titration fixes most of it.
monitorResting heart rate ticks up a few beats, the glucagon arm’s tell. Check yours now and then; in the trials it rose early and eased with time.
anecdotalNight sweats and running warm, reported widely and blamed on the raised metabolic burn. Annoying rather than dangerous, and a sign the third arm is working.
monitorThe GLP-1 class carries a small pancreatitis signal. Severe upper-belly pain that does not pass is a stop-and-get-checked, not a push-through.

Where to buy

$60 / 20mg vial$3.00/mg
✓ verified Sep 12
$105 / 30mg vial$3.50/mg
✓ verified Sep 12
$150 / 30mg vial$5.00/mg
✓ verified Sep 12
$160 / 30mg vial$5.33/mg
✓ verified Sep 12
$120 / 20mg vial$6.00/mg
✓ verified Sep 12
$199.99 / 20mg vial$10.00/mg
⚠ ⚠ Unreachable since Sep 11
✓ verified Sep 8
$90 / unit
✓ verified Sep 12

Prices move. Links are affiliate links; they never change a ranking, and scores are set before the deal exists.